Cargando…

Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer

Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gąsiorkiewicz, Bartosz Mateusz, Koczurkiewicz-Adamczyk, Paulina, Piska, Kamil, Pękala, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960624/
https://www.ncbi.nlm.nih.gov/pubmed/33159673
http://dx.doi.org/10.1007/s10637-020-01032-y
_version_ 1783665090973663232
author Gąsiorkiewicz, Bartosz Mateusz
Koczurkiewicz-Adamczyk, Paulina
Piska, Kamil
Pękala, Elżbieta
author_facet Gąsiorkiewicz, Bartosz Mateusz
Koczurkiewicz-Adamczyk, Paulina
Piska, Kamil
Pękala, Elżbieta
author_sort Gąsiorkiewicz, Bartosz Mateusz
collection PubMed
description Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic efficacy. Autophagy modulation has become an important area of interest regarding the aforementioned topic. Autophagy is a highly conservative cellular self-digestive process implicated in response to multiple environmental stressors. The high basal level of autophagy is a common phenomenon in cisplatin-resistant cancer cells which is thought to grant survival benefit. However current evidence supports the role of autophagy in either promoting or limiting carcinogenesis depending on the context. This encourages the search of substances modulating the process to alleviate cisplatin resistance. Such a strategy encompasses not only simple autophagy inhibition but also harnessing the process to induce autophagy-dependent cell death. In this paper, we briefly describe the mechanism of cisplatin resistance with a special emphasis on autophagy and we give an extensive literature review of potential substances with cisplatin chemosensitising properties related to autophagy modulation.
format Online
Article
Text
id pubmed-7960624
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-79606242021-04-01 Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer Gąsiorkiewicz, Bartosz Mateusz Koczurkiewicz-Adamczyk, Paulina Piska, Kamil Pękala, Elżbieta Invest New Drugs Review Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic efficacy. Autophagy modulation has become an important area of interest regarding the aforementioned topic. Autophagy is a highly conservative cellular self-digestive process implicated in response to multiple environmental stressors. The high basal level of autophagy is a common phenomenon in cisplatin-resistant cancer cells which is thought to grant survival benefit. However current evidence supports the role of autophagy in either promoting or limiting carcinogenesis depending on the context. This encourages the search of substances modulating the process to alleviate cisplatin resistance. Such a strategy encompasses not only simple autophagy inhibition but also harnessing the process to induce autophagy-dependent cell death. In this paper, we briefly describe the mechanism of cisplatin resistance with a special emphasis on autophagy and we give an extensive literature review of potential substances with cisplatin chemosensitising properties related to autophagy modulation. Springer US 2020-11-07 2021 /pmc/articles/PMC7960624/ /pubmed/33159673 http://dx.doi.org/10.1007/s10637-020-01032-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Gąsiorkiewicz, Bartosz Mateusz
Koczurkiewicz-Adamczyk, Paulina
Piska, Kamil
Pękala, Elżbieta
Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
title Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
title_full Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
title_fullStr Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
title_full_unstemmed Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
title_short Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
title_sort autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960624/
https://www.ncbi.nlm.nih.gov/pubmed/33159673
http://dx.doi.org/10.1007/s10637-020-01032-y
work_keys_str_mv AT gasiorkiewiczbartoszmateusz autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer
AT koczurkiewiczadamczykpaulina autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer
AT piskakamil autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer
AT pekalaelzbieta autophagymodulatingagentsaschemosensitizersforcisplatintherapyincancer